GSK plc vs PTC Therapeutics, Inc.: SG&A Expense Trends

GSK vs PTC: A Decade of SG&A Expense Evolution

__timestamp	GSK plc	PTC Therapeutics, Inc.
Wednesday, January 1, 2014	8246000000	44820000
Thursday, January 1, 2015	9232000000	82080000
Friday, January 1, 2016	9366000000	97130000
Sunday, January 1, 2017	9672000000	121271000
Monday, January 1, 2018	9915000000	153548000
Tuesday, January 1, 2019	11402000000	202541000
Wednesday, January 1, 2020	11456000000	245164000
Friday, January 1, 2021	10975000000	285773000
Saturday, January 1, 2022	8372000000	325998000
Sunday, January 1, 2023	9385000000	332540000

Igniting the spark of knowledge

SG&A Expense Trends: GSK plc vs PTC Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, GSK plc and PTC Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. GSK plc, a stalwart in the industry, has seen its SG&A expenses fluctuate, peaking in 2020 with a 39% increase from 2014, before a slight dip in 2022. Meanwhile, PTC Therapeutics, Inc., a burgeoning biotech firm, has consistently increased its SG&A spending, reflecting a strategic push for growth. From 2014 to 2023, PTC's expenses surged by over 640%, highlighting its aggressive market expansion. This comparison not only underscores the differing growth strategies but also offers insights into how established and emerging companies allocate resources to maintain competitive edges.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025